Role of a DEF/Y Motif in Histone H2A-H2B Recognition and Nucleosome Editing
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Gene Family: Gene Duplication and Retrotransposon Insertion
21 Bucentaur (Bcnt)1 Gene Family: Gene Duplication and Retrotransposon Insertion Shintaro Iwashita and Naoki Osada Iwaki Meisei University / National Institute of Genetics Japan 1. Introduction Members of multiple gene families in higher organisms allow for more refined cellular signaling networks and structural organization toward more stable physiological homeostasis. Gene duplication is one the most powerful ways of providing an opportunity to create a novel gene(s) because a novel function might be acquired without the loss of the original gene function (Ohno, 1970). Gene duplication can result from unequal crossing over by recombination, retroposition of cDNA, or whole-genome duplication. Furthermore, a replication-based mechanism of change in gene copy number has been proposed recently (Hastings et al., 2009). Gene duplication generated by retroposition is frequently accompanied by deleterious effects because the insertion of cDNA into the genome is nearly random or unlinks the original gene location resulting in an alteration of the original vital functions of the target genes. Thus retroelements such as transposable elements and endogenous retroviruses have been thought of as “selfish”. On the other hand, gene duplication caused by unequal crossing over generally results in tandem alignment, which less frequently disrupts the functions of other genes. Recent genome-wide studies have demonstrated that retroelements can definitely contribute to the creation of individual novel genes and the modulation of gene expression, which allows for the dynamic diversity of biological systems, such as placental evolution (Rawn & Cross, 2008). It is now recognized that tandem duplication and retroposition are among the key factors that initiate the creation of novel gene family members (Brosius, 2005; Sorek, 2007; Kaessmann, 2010). -
A. Cellular Senescence
Generation of antisense RNAs at convergent gene loci in cells undergoing senescence Maharshi Krishna Deb To cite this version: Maharshi Krishna Deb. Generation of antisense RNAs at convergent gene loci in cells undergo- ing senescence. Human genetics. Université Paul Sabatier - Toulouse III, 2016. English. NNT : 2016TOU30274. tel-03209213 HAL Id: tel-03209213 https://tel.archives-ouvertes.fr/tel-03209213 Submitted on 27 Apr 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 5)µ4& &OWVFEFMPCUFOUJPOEV %0$503"5%&-6/*7&34*5²%&506-064& %ÏMJWSÏQBS Université Toulouse 3 Paul Sabatier (UT3 Paul Sabatier) 1SÏTFOUÏFFUTPVUFOVFQBS DEB Maharshi Krishna -F mercredi 30 mars 2016 5Jtre : Generation of antisense RNAs at convergent gene loci in cells undergoing senescence École doctorale et discipline ou spécialité : ED BSB : Génétique moléculaire 6OJUÏEFSFDIFSDIF CNRS-UMR5088; LBCMCP %JSFDUFVS T EFʾÒTF Dr. TROUCHE Didier Co-Directeur/trice(s) de Thèse : Dr. NICOLAS Estelle 3BQQPSUFVST Prof. GILSON Eric, Dr. LIBRI Domenico, Dr. VERDEL Andre "VUSF T NFNCSF T EVKVSZ Prof. GLEIZES Pierre Emmanuel, President of Jury Dr. TROUCHE Didier, Thesis Supervisor This thesis is dedicated to any patients who may get cured with treatments manifesting from this work. -
Supplementary Data
SUPPLEMENTARY DATA A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma Santiago Demajo et al. 1 SUPPLEMENTARY DATA INDEX Supplementary Methods p. 3 Supplementary References p. 8 Supplementary Tables (S1 to S5) p. 9 Supplementary Figures (S1 to S15) p. 17 2 SUPPLEMENTARY METHODS Western blot, immunoprecipitation, and qRT-PCR Western blot (WB) analysis was performed as previously described (1), using cyclin D1 (Santa Cruz Biotechnology, sc-753, RRID:AB_2070433) and tubulin (Sigma-Aldrich, T5168, RRID:AB_477579) antibodies. Co-immunoprecipitation assays were performed as described before (2), using cyclin D1 antibody (Santa Cruz Biotechnology, sc-8396, RRID:AB_627344) or control IgG (Santa Cruz Biotechnology, sc-2025, RRID:AB_737182) followed by protein G- magnetic beads (Invitrogen) incubation and elution with Glycine 100mM pH=2.5. Co-IP experiments were performed within five weeks after cell thawing. Cyclin D1 (Santa Cruz Biotechnology, sc-753), E2F4 (Bethyl, A302-134A, RRID:AB_1720353), FOXM1 (Santa Cruz Biotechnology, sc-502, RRID:AB_631523), and CBP (Santa Cruz Biotechnology, sc-7300, RRID:AB_626817) antibodies were used for WB detection. In figure 1A and supplementary figure S2A, the same blot was probed with cyclin D1 and tubulin antibodies by cutting the membrane. In figure 2H, cyclin D1 and CBP blots correspond to the same membrane while E2F4 and FOXM1 blots correspond to an independent membrane. Image acquisition was performed with ImageQuant LAS 4000 mini (GE Healthcare). Image processing and quantification were performed with Multi Gauge software (Fujifilm). For qRT-PCR analysis, cDNA was generated from 1 µg RNA with qScript cDNA Synthesis kit (Quantabio). qRT–PCR reaction was performed using SYBR green (Roche). -
Identification of Differentially Methylated Cpg
biomedicines Article Identification of Differentially Methylated CpG Sites in Fibroblasts from Keloid Scars Mansour A. Alghamdi 1,2 , Hilary J. Wallace 3,4 , Phillip E. Melton 5,6 , Eric K. Moses 5,6, Andrew Stevenson 4 , Laith N. Al-Eitan 7,8 , Suzanne Rea 9, Janine M. Duke 4, 10 11 4,9,12 4, , Patricia L. Danielsen , Cecilia M. Prêle , Fiona M. Wood and Mark W. Fear * y 1 Department of Anatomy, College of Medicine, King Khalid University, Abha 61421, Saudi Arabia; [email protected] 2 Genomics and Personalized Medicine Unit, College of Medicine, King Khalid University, Abha 61421, Saudi Arabia 3 School of Medicine, The University of Notre Dame Australia, Fremantle 6959, Australia; [email protected] 4 Burn Injury Research Unit, School of Biomedical Sciences, Faculty of Health and Medical Sciences, The University of Western Australia, Perth 6009, Australia; andrew@fionawoodfoundation.com (A.S.); [email protected] (J.M.D.); fi[email protected] (F.M.W.) 5 Centre for Genetic Origins of Health and Disease, Faculty of Health and Medical Sciences, The University of Western Australia, Perth 6009, Australia; [email protected] (P.E.M.); [email protected] (E.K.M.) 6 School of Pharmacy and Biomedical Sciences, Faculty of Health Science, Curtin University, Perth 6102, Australia 7 Department of Applied Biological Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan; [email protected] 8 Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, -
ANP32B Deficiency Impairs Proliferation and Suppresses Tumor Progression by Regulating AKT Phosphorylation
Citation: Cell Death and Disease (2016) 7, e2082; doi:10.1038/cddis.2016.8 OPEN & 2016 Macmillan Publishers Limited All rights reserved 2041-4889/16 www.nature.com/cddis ANP32B deficiency impairs proliferation and suppresses tumor progression by regulating AKT phosphorylation S Yang1,6, L Zhou2,6, PT Reilly3, S-M Shen1,PHe1, X-N Zhu1, C-X Li1, L-S Wang4, TW Mak5, G-Q Chen*,1 and Y Yu*,1 The acidic leucine-rich nuclear phosphoprotein 32B (ANP32B) is reported to impact normal development, with Anp32b-knockout mice exhibiting smaller size and premature aging. However, its cellular and molecular mechanisms, especially its potential roles in tumorigenesis, remain largely unclear. Here, we utilize 'knockout' models, RNAi silencing and clinical cohorts to more closely investigate the role of this enigmatic factor in cell proliferation and cancer phenotypes. We report that, compared with Anp32b wild- type (Anp32b+/+) littermates, a broad panel of tissues in Anp32b-deficient (Anp32b− / −) mice are demonstrated hypoplasia. Anp32b− / − mouse embryo fibroblast cell has a slower proliferation, even after oncogenic immortalization. ANP32B knockdown also significantly inhibits in vitro and in vivo growth of cancer cells by inducing G1 arrest. In line with this, ANP32B protein has higher expression in malignant tissues than adjacent normal tissues from a cohort of breast cancer patients, and its expression level positively correlates with their histopathological grades. Moreover, ANP32B deficiency downregulates AKT phosphorylation, which involves its regulating effect on cell growth. Collectively, our findings suggest that ANP32B is an oncogene and a potential therapeutic target for breast cancer treatment. Cell Death and Disease (2016) 7, e2082; doi:10.1038/cddis.2016.8; published online 4 February 2016 The acidic leucine-rich nuclear phosphoprotein 32 kDa lethality and reduced body weight,22–25 indicating a greater (ANP32) protein family are characterized by a N-terminal importance of Anp32b in normal development. -
Identifying Genetic Risk Factors for Coronary Artery Angiographic Stenosis in a Genetically Diverse Population
Please do not remove this page Identifying Genetic Risk Factors for Coronary Artery Angiographic Stenosis in a Genetically Diverse Population Liu, Zhi https://scholarship.miami.edu/discovery/delivery/01UOML_INST:ResearchRepository/12355224170002976?l#13355497430002976 Liu, Z. (2016). Identifying Genetic Risk Factors for Coronary Artery Angiographic Stenosis in a Genetically Diverse Population [University of Miami]. https://scholarship.miami.edu/discovery/fulldisplay/alma991031447280502976/01UOML_INST:ResearchR epository Embargo Downloaded On 2021/09/26 20:05:11 -0400 Please do not remove this page UNIVERSITY OF MIAMI IDENTIFYING GENETIC RISK FACTORS FOR CORONARY ARTERY ANGIOGRAPHIC STENOSIS IN A GENETICALLY DIVERSE POPULATION By Zhi Liu A DISSERTATION Submitted to the Faculty of the University of Miami in partial fulfillment of the requirements for the degree of Doctor of Philosophy Coral Gables, Florida August 2016 ©2016 Zhi Liu All Rights Reserved UNIVERSITY OF MIAMI A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy IDENTIFYING GENETIC RISK FACTORS FOR CORONARY ARTERY ANGIOGRAPHIC STENOSIS IN A GENETICALLY DIVERSE POPULATION Zhi Liu Approved: ________________ _________________ Gary W. Beecham, Ph.D. Liyong Wang, Ph.D. Assistant Professor of Human Associate Professor of Human Genetics Genetics ________________ _________________ Eden R. Martin, Ph.D. Guillermo Prado, Ph.D. Professor of Human Genetics Dean of the Graduate School ________________ Tatjana Rundek, M.D., Ph.D. Professor of Neurology LIU, ZHI (Ph.D., Human Genetics and Genomics) Identifying Genetic Risk Factors for Coronary Artery (August 2016) Angiographic Stenosis in a Genetically Diverse Population Abstract of a dissertation at the University of Miami. Dissertation supervised by Professor Gary W. -
Downloaded 18 July 2014 with a 1% False Discovery Rate (FDR)
UC Berkeley UC Berkeley Electronic Theses and Dissertations Title Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer Permalink https://escholarship.org/uc/item/0t47b9ws Author Spiciarich, David Publication Date 2017 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer by David Spiciarich A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Chemistry in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Carolyn R. Bertozzi, Co-Chair Professor David E. Wemmer, Co-Chair Professor Matthew B. Francis Professor Amy E. Herr Fall 2017 Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer © 2017 by David Spiciarich Abstract Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer by David Spiciarich Doctor of Philosophy in Chemistry University of California, Berkeley Professor Carolyn R. Bertozzi, Co-Chair Professor David E. Wemmer, Co-Chair Changes in glycosylation have long been appreciated to be part of the cancer phenotype; sialylated glycans are found at elevated levels on many types of cancer and have been implicated in disease progression. However, the specific glycoproteins that contribute to cell surface sialylation are not well characterized, specifically in bona fide human cancer. Metabolic and bioorthogonal labeling methods have previously enabled enrichment and identification of sialoglycoproteins from cultured cells and model organisms. The goal of this work was to develop technologies that can be used for detecting changes in glycoproteins in clinical models of human cancer. -
Primepcr™Assay Validation Report
PrimePCR™Assay Validation Report Gene Information Gene Name acidic (leucine-rich) nuclear phosphoprotein 32 family, member E Gene Symbol Anp32e Organism Mouse Gene Summary Description Not Available Gene Aliases 2810018A15Rik, AI047746, AI326868, CPD1, LANP-L, LANPL, mLANP-L RefSeq Accession No. NC_000069.6, NT_039240.8 UniGene ID Mm.218657 Ensembl Gene ID ENSMUSG00000015749 Entrez Gene ID 66471 Assay Information Unique Assay ID qMmuCIP0034318 Assay Type Probe - Validation information is for the primer pair using SYBR® Green detection Detected Coding Transcript(s) ENSMUST00000165307, ENSMUST00000015893, ENSMUST00000168106, ENSMUST00000170125 Amplicon Context Sequence GGGGAAAGGAGGAGGACATGGAGATGAAGAAGAAGATTAACATGGAGTTGAAG AACAGAGCCCCGGAGGAGGTGACAGAGTTAGTCCTCGATAATTGCTTGTGTGTC AATGGGGAAATCGAAGGCCTGAA Amplicon Length (bp) 100 Chromosome Location 3:95929580-95933967 Assay Design Intron-spanning Purification Desalted Validation Results Efficiency (%) 100 R2 0.9995 cDNA Cq 18.9 cDNA Tm (Celsius) 81 gDNA Cq 42.75 Specificity (%) 100 Information to assist with data interpretation is provided at the end of this report. Page 1/4 PrimePCR™Assay Validation Report Anp32e, Mouse Amplification Plot Amplification of cDNA generated from 25 ng of universal reference RNA Melt Peak Melt curve analysis of above amplification Standard Curve Standard curve generated using 20 million copies of template diluted 10-fold to 20 copies Page 2/4 PrimePCR™Assay Validation Report Products used to generate validation data Real-Time PCR Instrument CFX384 Real-Time PCR Detection System Reverse Transcription Reagent iScript™ Advanced cDNA Synthesis Kit for RT-qPCR Real-Time PCR Supermix SsoAdvanced™ SYBR® Green Supermix Experimental Sample qPCR Mouse Reference Total RNA Data Interpretation Unique Assay ID This is a unique identifier that can be used to identify the assay in the literature and online. -
Species Specific Differences in Use of ANP32 Proteins by Influenza a Virus
Edinburgh Research Explorer Species specific differences in use of ANP32 proteins by influenza A virus Citation for published version: Long, JS, Idoko-Akoh, A, Mistry, B, Goldhill, DH, Staller , E, Schreyer, J, Ross, C, Goodbourn, S, Shelton, H, Skinner, MA, Sang, H, McGrew, M & Barclay, WS 2019, 'Species specific differences in use of ANP32 proteins by influenza A virus', eLIFE, vol. N/A, 2019;8:e45066. https://doi.org/10.7554/eLife.45066 Digital Object Identifier (DOI): 10.7554/eLife.45066 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: eLIFE Publisher Rights Statement: This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 11. Oct. 2021 -
Population-Haplotype Models for Mapping and Tagging Structural Variation Using Whole Genome Sequencing
Population-haplotype models for mapping and tagging structural variation using whole genome sequencing Eleni Loizidou Submitted in part fulfilment of the requirements for the degree of Doctor of Philosophy Section of Genomics of Common Disease Department of Medicine Imperial College London, 2018 1 Declaration of originality I hereby declare that the thesis submitted for a Doctor of Philosophy degree is based on my own work. Proper referencing is given to the organisations/cohorts I collaborated with during the project. 2 Copyright Declaration The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the licence terms of this work 3 Abstract The scientific interest in copy number variation (CNV) is rapidly increasing, mainly due to the evidence of phenotypic effects and its contribution to disease susceptibility. Single nucleotide polymorphisms (SNPs) which are abundant in the human genome have been widely investigated in genome-wide association studies (GWAS). Despite the notable genomic effects both CNVs and SNPs have, the correlation between them has been relatively understudied. In the past decade, next generation sequencing (NGS) has been the leading high-throughput technology for investigating CNVs and offers mapping at a high-quality resolution. We created a map of NGS-defined CNVs tagged by SNPs using the 1000 Genomes Project phase 3 (1000G) sequencing data to examine patterns between the two types of variation in protein-coding genes. -
B-Deficient Mouse Reveals a Hierarchy of ANP32 Importance In
Acidic nuclear phosphoprotein 32kDa (ANP32)B-deficient mouse reveals a hierarchy of ANP32 importance in mammalian development Patrick T. Reillya, Samia Afzalb,c, Chiara Gorrinib, Koren Luib, Yury V. Bukhmanb,1, Andrew Wakehamb, Jillian Haightb, Teo Wei Linga, Carol C. Cheungb, Andrew J. Eliab, Patricia V. Turnerd, and Tak Wah Maka,b,2 aDivision of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore 169610; bCampbell Family Cancer Research Institute, University Health Network, Toronto, ON, Canada M5G 2C1; cGraduate Program in Immunology, University of Toronto, Toronto, ON, Canada M5S 1A8; and dDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada N1G 2W1 Contributed by Tak Wah Mak, April 20, 2011 (sent for review February 18, 2011) The highly conserved ANP32 proteins are proposed to function in these studies has specifically excluded a particular ANP32 protein a broad array of physiological activities through molecular mech- as contributing to the activities examined. anisms as diverse as phosphatase inhibition, chromatin regulation, More recent work has demonstrated functions that are ex- caspase activation, and intracellular transport. On the basis of clusive to the ANP32B protein, at least in humans. First, previous analyses of mice bearing targeted mutations of Anp32a ANP32B, but not ANP32A, controls the expression of the den- or Anp32e, there has been speculation that all ANP32 proteins play dritic cell maturation factor CD83 by regulating the transport of redundant roles and are dispensable for normal development. its mRNA to the cytoplasm (22). Second, ANP32B modulates However, more recent work has suggested that ANP32B may in the activity of the transcription factor Kruppel-like factor 5 fact have functions that are not shared by other ANP32 family (KLF5), whereas ANP32A cannot (32). -
Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations
cancers Article Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression Can Li 1,2,†, Erik B. Wendlandt 3,†, Benjamin Darbro 4, Hongwei Xu 1, Gregory S. Thomas 3, Guido Tricot 1, Fangping Chen 2 , John D. Shaughnessy Jr. 1 and Fenghuang Zhan 1,* 1 Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA; [email protected] (C.L.); [email protected] (H.X.); [email protected] (G.T.); [email protected] (J.D.S.J.) 2 Department of Hematology, Xiangya Hospital, Central South University, Changsha 410008, China; [email protected] 3 Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA; [email protected] (E.B.W.); [email protected] (G.S.T.) 4 Cytogenetics and Molecular Laboratory, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work. Simple Summary: Multiple myeloma (MM) is the second most common hematological neoplasia with a high incidence in elderly populations. The disease is characterized by a severe chaos of genomic abnormality. Comprehensive examinations of myeloma cytogenetics are needed for better understanding of MM and potential application to the development of novel therapeutic regiments. Here we utilized gene expression profiling and CytoScan HD genomic arrays to investigate molecular Citation: Li, C.; Wendlandt, E.B.; alterations in myeloma leading to disease progression and poor clinical outcomes. We demonstrates Darbro, B.; Xu, H.; Thomas, G.S.; that genetic abnormalities within MM patients exhibit unique protein network signatures that can be Tricot, G.; Chen, F.; Shaughnessy, J.D., exploited for implementation of existing therapies targeting key pathways and the development of Jr.; Zhan, F.